References
- Brzyżkiewicz H., Konduracka E., Gajos G., Janion M.: Incidence of chronic heart failure with preserved left ventricular ejection fraction in patients with hypertension and isolated mild diastolic dysfunction. Pol. Arch. Med. Wewn., 2016; 126: 12–18.
- Czarnecka D., Jankowski P., Kopeć G., Pająk A., Podolec J., Zdrojewski T., Drygas W., Małecki M., Nowicka G., Windak A., et al.: Polish Forum for Prevention Guidelines on Hypertension: Update 2017. Kardiol. Pol., 2017; 75: 282–285.
- Eren E., Yilmaz N., Aydin O., Ellidağ H.Y.: Anticipatory role of high density lipoprotein and endothelial dysfunction: An overview. Open. Biochem. J., 2014; 8: 100–106.
- Banaszewska A., Baszczuk A., Kopczyński Z., Thielemann A., Kopczyński P.: The role of paraoxonase 1 (EC 3.1.8.1) in the development of atherosclerosis. Post. Biol. Kom., 2014; 41: 429–444.
- Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parrno S.L., La Du B.N.: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest., 1998; 101: 1581–1590.
- Hine D., Mackness B., Mackness M.: Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life, 2012; 64: 157–161.
- Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J.: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1998; 394: 284–287.
- Tavori M., Aviram S., Khatib S., Musa R., Nitecki S., Hoffman A., Vaya J.: Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects. Free Radic. Biol. Med., 2009; 46: 607–615.
- Shunmoogam N., Naidoo P., Chilton R.: Paraoxonase (PON)-1: A brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc. Health Risk Manag., 2018; 14: 137-143.
- Zhao Y., Ma Y., Fang Y., Liu L., Wu S., Fu D., Wang X.: Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies. Mol. Genet. Metab., 2012; 105: 141–148.
- Kunutsor S.K., Bakker S.J., James R.W., Dullaart R.P.: Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. Atherosclerosis, 2016; 245: 143–154.
- Zhou C., Cao J., Shang L., Tong C., Hu H., Wang H., Fan D., Yu H.: Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis. Markers, 2013; 35: 97–103.
- Michalak S., Ambrosius W., Wysocka E., Dziarmaga M., Juszkat R., Wykretowicz A., Kozubski W.: The early effect of carotid artery stenting on antioxidant capacity and oxidative stress in patients with carotid artery stenosis. Oxid. Med. Cell. Longev., 2016; 2016: 1789596.
- Chen X., Wu Y., Liu L., Su Y., Peng Y., Jiang L., Liu X., Huang D.: Relationship between high density lipoprotein antioxidant activity and carotid arterial intima-media thickness in patients with essential hypertension. Clin. Exp. Hypertens., 2010; 32: 13–20.
- Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D.M., Chroni A., Yonekawa K., Stein S., Schaefer N., et al.: Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest., 2011; 121: 2693–2708.
- Xu S., Ogura S., Chen J., Little P.J., Moss J., Liu P.: LOX-1 in atherosclerosis: Biological functions and pharmacological modifiers. Cell. Mol. Life Sci., 2013; 70: 2859–2872.
- Charakida M., Besler C., Batuca J.R., Sangle S., Marques S., Sousa M., Wang G., Touisoulis D., Alves J.D., Loukogeorgakis S.P., et al.: Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA, 2009; 302: 1210–1217.
- Adams V., Besler C., Fischer T., Riwanto M., Noack F., Höllriegel R., Oberbach A., Jehmlich N., Völker U., Winzer E.B., et al.: Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ. Res., 2013; 113: 1345–1355.
- Ayashi S., Assareh A.R., Jalali M.T., Olapour S., Yaghooti H.: Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label study. Indian. J. Pharmacol., 2016; 48: 372–376.
- Fridman O., Gariglio L., Riviere S., Porcile R., Fuchs A., Potenzoni M.: Paraoxonase 1 gene polymorphisms and enzyme activities in coronary artery disease and its relationship to serum lipids and glycemia. Arch. Cardiol. Mex., 2016; 86: 350–357.
- Rybka J., Kupczyk D., Kędziora-Kornatowska K., Motyl J., Czuczejko J., Szewczyk-Golec K., Kozakiewicz M., Pawluk H., Carvalho L.A., Kędziora J.: Glutathione-related antioxidant defense system in elderly patients treated for hypertension. Cardiovasc. Toxicol., 2011; 11: 1–9.
- Mineo C., Shaul P.W.: PON-dering differences in HDL function in coronary artery disease. J. Clin. Invest., 2011; 121: 2545–2548.
- Rahmani M., Raiszadeh F., Allahverdian S., Kiaii S., Navab M., Azizi F.: Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis, 2002; 162: 381–389.
- Göçmen A.Y., Gümüşlü S., Semiz E.: Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Clin. Cardiol., 2004; 27: 426–430.
- Shekhanawar M., Shekhanawar S.M., Krisnaswamy D., Indumati V., Satishkumar D., Vijay V., Rajeshwari T., Amareshwar M.: The role of “paraoxonase-1 activity” as an antioxidant in coronary artery diseases. J. Clin. Diagn. Res., 2013; 7: 1284–1287.
- Yan L.R., Wang D.X., Liu H., Zhang X.X., Zhao H., Hua L., Xu P., Li Y.S.: A pro-atherogenic HDL profile in coronary heart disease patients: An iTRAQ labelling-based proteomic approach. PLoS One, 2014; 9: e98368.
- Alaminos-Castillo M.Á., Ho-Pagaro A., García-Serrano S., Santiago-Fernandez C., Rodríguez-Pacheco F., Garrido-Sanchez L., Rodriguez C., Valdes S., Gonzalo M., Moreno-Ruiz F.J., et al.: Increased PON lactonase activity in morbidly obese patients is associated with impaired lipid profile. Int. J. Clin. Pract., 2019; 73: e13315.
- Aslan M., Horoz M., Sabuncu T., Celik H., Selek S.: Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Pol. Arch. Med. Wewn., 2011; 121: 181–186.
- van Himbergen T.M., Roest M., de Graaf J., Jansen E.H., Hattori H., Kastelein J.J., Voorbij H.A., Stalenhoef A.F., van Tits L.J.: Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. Lipid Res., 2005; 46: 445-451.
- Daly C., Fitzgerald A.P., O’Callaghan P., Collins P., Cooney M.T., Graham I.M., COMAC Group.: Homocysteine increases the risk associate with hyperlipidaemia. Eur. J. Cardiovasc. Prev. Rehabil., 2009; 16: 150–155.
- Guéant-Rodriguez R.M., Spada R., Moreno-Garcia M., Anello G., Bosco P., Lagrost L., Romano A., Elia M., Guéant J.L.: Homocysteine is a determinant of ApoA-I and both are associated with ankle brachial index, in an ambulatory elderly population. Atherosclerosis, 2011; 214: 480–485.
- Baszczuk A., Musialik K., Kopczyński J., Thielemann A., Kopczyński Z., Kęsy L., Dopierała G.: Hyperhomocysteinemia, lipid and lipoprotein disturbances in patients with primary hypertension. Adv. Med. Sci., 2014; 59: 68–73.
- Ferretti G., Bacchetti T., Marotti E., Curatola G.: Effect of homocysteinylation on human high-density lipoproteins: A correlation with paraoxonase activity. Metabolism, 2003; 52: 146–151.
- Liao D., Tan H., Hui R.,, Li Z., Jiang X., Gaubatz J., Yang F., Durante W., Chan L., Schafer A.I., et al.: Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ. Res., 2006; 99: 598–606.
- Perła-Kaján J., Jakubowski H.: Paraoxonase 1 and homocysteine metabolism. Amino Acids, 2012; 43: 1405–1417.
- Locsey L., Seres I., Sztanek F., Harangi M., Padra J., Kovacs D., Fedor R., Asztalos L., Paragh G.: Relationship between serum paraoxonase and homocysteine thiolactonase activity, adipokines, and asymmetric dimethyl arginine concentrations in renal transplant patients. Transplant. Proc., 2013; 45: 3685–3687.
- Karikas G.A., Kriebardis A., Samara I., Schulpis K., Papachristodoulou M., Fytou-Pallikari A.: Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece. Clin. Chem. Lab. Med., 2006; 44: 623–627.
- Holven K.B., Aukrust P., Retterstøl K., Otterdal K., Bjerkeli V., Ose L., Nenseter M.S., Halvorsen B.: The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. J. Nutr., 2008; 138: 2070–2075.
- Tang W.H., Hartiala J., Fan Y., Wu Y., Stewart A.F., Erdmann J., Kathiresan S., CARDIoGRAM Consortium, Roberts R., McPherson R., et al.: Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol., 2012; 32: 2803–2812.
- Abelló D., Sancho E., Camps J., Joven J.: Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: A systematic review. Int. J. Mol. Sci., 2014; 15: 20997–21010.